Skip to main content
Premium Trial:

Request an Annual Quote

Mireven Secures Additional Funding


Australian microRNA drug developer Mireven said last week that it has received an additional A$500,000 ($511,000) from early-stage investment group Medical Research Commercialization Fund, bringing the total investment MRCF has made in the company to A$1.1 million.

According to Mireven, the additional investment is the result of its achievement of undisclosed technical and commercial milestones. The company is developing a mimic of miR-7 as a treatment for cancer.

“This pivotal funding from the MRCF allows Mireven to expand and undertake in vivo studies to examine the delivery of miR-7 with independent parties,” Mireven Chairman Stephen Thompson said in a statement.

Last month, Mireven signed a deal to evaluate Silence Therapeutics' delivery technologies with its miR-7 mimetic (GSN 8/23/2012). It said that it has also inked a second deal with an undisclosed “international company” focused on “positioning miR-7 as a cancer therapeutic.”

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.